Noxafil shortage — US supply status & alternatives

Noxafil

—

🇦🇺 AUST R 115556 · Merck Sharp & Dohme Australia Pty Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇭 CH

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Noxafil
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No

Registrations on file	8

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~1 month

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇺🇸

United States

FDA MedWatch · 1mo ago

High

🇨🇭

Switzerland

Swissmedic · 2d ago

Medium

🇪🇸

Spain

AEMPS · 1h ago

Resolved

Verified timeline regulator events

🇨🇭 1 July 2026

medium reported

🇨🇭 28 June 2026

medium reported

🇨🇭 27 June 2026

medium reported

🇨🇭 26 June 2026

medium reported

🇨🇭 22 June 2026

medium reported

🇨🇭 21 June 2026

medium reported

Sources official regulators

🇪🇸

AEMPS

verified 1h ago

verify ↗

🇨🇭

Swissmedic

verified 2d ago

verify ↗

🇺🇸

FDA MedWatch

verified 1mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders8 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
NOXAFIL posaconazole	40mg	—	🇦🇺 AU	Merck Sharp & Dohme Australia Pty Ltd	Active
NOXAFIL	40mg/mL	suspension	🇺🇸 US	Merck Sharp & Dohme LLC	Active
NOXAFIL	300mg/1	suspension	🇺🇸 US	Merck Sharp & Dohme LLC	Active
NOXAFIL	100mg/1	tablet	🇺🇸 US	Merck Sharp & Dohme LLC	Active
NOXAFIL	18mg/mL	solution	🇺🇸 US	Merck Sharp & Dohme LLC	Active
NOXAFIL posaconazole	300 mg	—	🇦🇺 AU	Merck Sharp & Dohme Australia Pty Ltd	Active
NOXAFIL posaconazole	100mg	—	🇦🇺 AU	Merck Sharp & Dohme Australia Pty Ltd	Active
Noxafil	—	—	🌐 EU	Merck Sharp and Dohme B.V	Active

Mederti Drug Report

Generated 4 July 2026 · Australia market · 3 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.